CSPHF (CStone Pharmaceuticals) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CSPHF CStone Pharmaceuticals CSPHF
47 GF Score
Price $0.71
GF Value $0.15
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is CStone Pharmaceuticals Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

CSPHF
47GF Score
CStone Pharmaceuticals CSPHF
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is CStone Pharmaceuticals (CSPHF) Overvalued in 2026?

Based on GuruFocus' analysis, CStone Pharmaceuticals stock appears to be overvalued. The current stock price of $0.71 is trading 373.3% above its estimated GF Value™ of $0.15. GuruFocus considers CStone Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for CSPHF:

  • Interest Received:
  • GF Value™: $0.15 vs. price of $0.71 (373.3% above fair value)
  • GF Score™: 47/100 with 7 warning signs

No single metric tells the full story. See the CSPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CStone Pharmaceuticals Business Description

Other Exchanges 02616:Hong KongPH4:Germany
Address 218 Xinghu Street, C1 Building, North Block, Suzhou Industrial Park, Suzhou, CHN, 215123
CStone Pharmaceuticals is engaged in developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment. The Group has been operating in one reportable segment, being the research and development of high-complex biopharmaceutical products, the sale of pharmaceutical products, and provide license of its IP or commercialisation licenses to customers.
47GF Score

Get the complete analysis for CSPHF

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.71
Price
$0.15
GF Value